Educational content on VJHemOnc is intended for healthcare professionals only. By visiting this website and accessing this information you confirm that you are a healthcare professional.

Share this video  

COMy 2022 | Lenalidomide’s place in the myeloma treatment landscape

Paola Neri • 13 May 2022
COMy 2022
Multiple Myeloma Bortezomib Daratumumab Dexamethasone Lenalidomide Pomalidomide

Lenalidomide is an immunomodulatory drug (IMiD) used for the treatment of myeloma and is known to provide significant clinical benefits to patients. In this video, Paola Neri, MD, PhD, University of Calgary, Calgary, AB, Canada, briefly discusses lenalidomide’s place in the myeloma treatment armamentarium, highlighting its use in triplet and quadruplet combinations. Dr Neri also discusses the benefit of using lenalidomide for maintenance therapy, and the potential benefit of using other CELMoDs and IMiDs for the treatment of myeloma. This interview took place at the 8th World Congress on Controversies in Multiple Myeloma (COMy) 2022, held in Paris, France.

More from Paola Neri

1:45
Using the available repertoire of bispecific antibodies for treating multiple myeloma
Paola Neri • 17 Feb 2024
1:20
Antigen loss as a key driver of resistance to anti-BCMA T-cell therapies in myeloma
Paola Neri • 17 Feb 2024
Resistance mechanisms mediated by the microenvironment in multiple myeloma
Charlotte Pawlyn et al. • 15 Apr 2023
1:51
Optimizing immunotherapy in myeloma: tumor profiling, mutations & characterizing T-cell fitness
Paola Neri • 12 May 2023

Related Videos

0:59
Looking forward to COMy 2024: celebrating 10 years
Mohamad Mohty • 17 Apr 2024
0:57
Overcoming barriers to treating older patients with myeloma
Sergio Giralt • 16 Apr 2024
1:01
The potentially curative role of CAR-T therapy in myeloma
Sergio Giralt • 16 Apr 2024
1:45
Expanded approval of cilta-cel in myeloma: the value of bringing CAR-T cells into earlier lines
Monika Engelhardt • 16 Apr 2024
The content of VJHemOnc is intended for healthcare professionals